Search Results

Clinical insights on tachyphylaxis, tolerance, and kinetic-based therapeutics. < Back How Signaling Kinetics kinetics, the temporal dynamics of receptor activation and downstream signaling, directly influence therapeutic spans tachyphylaxis mechanisms in beta-agonist therapy, tolerance development with opioid agonists, and therapeutic pharmacologists, drug discovery scientists, and translational researchers working on temporal aspects of GPCR therapeutics specializing in kinetic analysis of drug action and the application of binding and signaling kinetics to therapeutic

technology platform deciphering cell signaling pathways combined with AI-based approaches to elucidate structure the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

regulate over 800 receptors, why "non-canonical" GPCRs are nature's own biased receptors, and building a structural How two structurally similar proteins orchestrate such functional diversity across an entire receptor His research focuses on the structural and functional basis of GPCR–beta-arrestin interactions, combining Scientific Themes of the Conversation The structural and functional basis of GPCR–beta-arrestin coupling Episode Timeline 00:00 Introduction 02:15 From DNA quadruplexes to GPCR structural biology 06:32 The

Schwartz, and worked closely with Dr Birgitte Holst studying structural and mechanistic properties of Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

Rho, YAP, and the druggable FAK node CXCR3 and the chemokine axis that gates immunotherapy response Structural The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients Team science is structural, not decorative. responds to checkpoint inhibitors 20:28 GαQ, uveal melanoma, and the failure of the textbook pathway 41:27 Structural

Xenopus oocytes, electrophysiology, molecular pharmacology, and the use of informatics to mine sequence, structural The CGRP story illustrates how structural biology and pharmacology intersect with corporate decisions Later hepatotoxicity concerns and the success of antibody therapeutics further shifted strategy. He argues that integrating structural biology, computational pharmacology, and genetics may still be

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

With a deep focus on structure-based drug design, Jens discusses how his lab bridges simulation and experiment—and From virtual screening of billions of molecules to leveraging AlphaFold for structure prediction, Jens You’ll Learn Why Jens Carlsson believes modeling should predict , not just explain How his team uses structure-based collaborations between modelers and experimentalists are more vital than ever How AlphaFold is shaking up structural a research career Who Should Listen GPCR scientists and pharmacologists Computational chemists and structural

I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.

collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation

has reached only about 166 of them, leaving more than 250 receptors unstudied at anything close to therapeutic Nikolaus Heveker's lab at the CHU Sainte-Justine Research Center on chemokine receptor structure–function Splice variants aren't just structural — they signal differently. During the past 2 decades, my research mainly focused on chemokine receptor structure/function relationships

into industry, and his role leading and shaping multidisciplinary teams for screening and innovative therapeutics How advanced assay design is essential for translating cell-based GPCR signals to therapeutic outcomes Martin Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic Marro’s career advanced through roles at Novartis and Tectonic Therapeutic, contributing to projects across key therapeutic areas—spanning metabolic, cardiovascular, and gastrointestinal diseases.

He earned his PhD in Physics at the same university, focusing on in silico structural vaccinology and Now in a tenure-track position, his research spans the development of computational methods such as structure-based Scholar ResearchGate Bysky App : @ riccardocapelli.bsky.social Twitter X : @ ric_capelli Computational Structural

Ray Stevens in 2013 solving several GPCR crystal structures, including that of the first serotonin receptor Bryan Roth where I established GPCR structural biology and learned the ins and outs of molecular pharmacology started my own lab at the Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function

signaling mechanisms employed by these atypical 7-transmembrane receptors, combining biochemical and structural begun studying GPCR signaling pathways that operate within the primary cilium, a tiny antenna-shaped structure Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure

Antonella Di Pizio on building computational models for GPCRs with almost no crystal structures and almost No crystal structures exist for most of them, sequence identity within the TAS2R family hovers between her PhD in computational medicinal chemistry before spending a formative period in Gerhard Klebe's structural Unlike bitter taste receptors, which share only 5–10% sequence identity with available structural templates relations based on the structure of the receptor."

He earned his PhD at MIT in the laboratory of Lawrence Stern, where he studied structure-function relationships He earned his Ph.D. at the Massachusetts Institute of Technology, where he studied MHC class II structure-function record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

With hundreds of subtypes and very few known ligands, the structure–function relationships remain largely .” – Alessandro Nicoli He explained how AlphaFold’s predictions, surprisingly close to experimental structures More structures, better tools, and deeper insights into the elegant, complex world of GPCRs. By bridging structural prediction, molecular dynamics, and ligand discovery, his work not only deciphers Alessandro PhD work aims to fill these gaps by leveraging computational structure-based tools and develop

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)

The bottleneck in structure-guided ML isn't the algorithm. The panel agreed that the real limits are the availability of high-resolution GPCR structures and the The experience of a seasoned medicinal chemist mentally docking a molecule from a 2D structure is not The explosion of biomedical data such as in genomics, structural biology, and pharmacology can provide How can we best leverage these exciting new techniques in areas such as protein structure prediction,

Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke the AudetLab located at the Institute of Pharmacology of Sherbrooke and is an emerging leader in the structural

Communications, which she joined in April 2020, following three years on the editorial teams of Nature Structural Katarzyna handles submissions in structural biology, biophysics and biochemistry, with a particular focus

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications GPCR pharmacology, signaling, structural biology, allosteric modulation, biased agonism, assay design

He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

Brain’s work there primarily focused on structure prediction of GPCRs from sparse experimental data. of California in San Francisco to continue his training as a postdoctoral researcher where he used structural

company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics

I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

Companies present their services in a structured format so GPCR discovery teams can quickly identify Your structured home within the ecosystem The GPCR CRO Bank is a strong fit for companies that want to : Make their services or products easily discoverable within the GPCR ecosystem Present clear, structured